Creatine Phosphate


💊 Chemical information

Creatina, fosfato de; Creatine Phosphoric Acid; Fosfocreatine; Phosphocreatine. N-[Imino(phosphonoamino)-methyl]N-methylglycine.
Chemical formula: C4H10N3O5P = 211.1.
CAS — 67-07-2 (creatine phosphate); 922-32-7 (creatine phosphate disodium).
ATC — C01EB06.
ATC Vet — QC01EB06.

💊 Profile

Creatine is an endogenous substance found mainly in skeletal muscle of vertebrates. Creatine phosphate and its disodium salt have been tried in the treatment of cardiac disorders. Creatine phosphate has also been added to cardioplegic solutions. Creatine monohydrate has been tried in metabolic disorders and used as a dietary supplement. It is also under investigation for the treatment of Parkinson’s disease, motor neurone disease, Duchenne muscular dystrophy, and Huntington disease.
1. Pedone V, et al. An assessment of the activity of creatine phosphate (Neoton) on premature ventricular beats by continuous ECG monitoring in patients with coronary cardiac disease. Clin Trials J 1984; 21: 91
2. Ferraro S, et al. Acute and short-term efficacy of high doses of creatine phosphate in the treatment of cardiac failure. Curr Ther Res 1990; 47: 917–23
3. Mastoroberto P, et al. Creatine phosphate protection of the ischemic myocardium during cardiac surgery. Curr Ther Res 1992; 51: 37–45
4. Stöckler S, et al. Creatine replacement therapy in guanidinoacetate methyltransferase deficiency, a novel inborn error of metabolism. Lancet 1996; 348: 789–90
5. Mujika I, Padilla S. Creatine supplementation as an ergogenic aid for sports performance in highly trained athletes: a critical review. Int J Sports Med 1997; 18: 491–6
6. Juhn MS, Tarnopolsky M. Oral creatine supplementation and athletic performance: a critical review. Clin J Sport Med 1998; 8: 286–97. Correction. ibid. 1999; 9: 62
7. Benzi G. Is there a rationale for the use of creatine either as nutritional supplementation or drug administration in humans participating in a sport? Pharmacol Res 2000; 41: 255–64
8. Persky AM, Brazeau GA. Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacol Rev 2001; 53: 161–76
9. Mazzini L, et al. Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results. J Neurol Sci 2001; 191: 139–44
10. Groeneveld JG, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003; 53: 437–45
11. Persky AM, et al. Pharmacokinetics of the dietary supplement creatine. Clin Pharmacokinet 2003; 42: 557–74
12. Shefner JM, et al. A clinical trial of creatine in ALS. Neurology 2004; 63: 1656–61
13. Ellis AC, Rosenfeld Jo. The role of creatine in the management of amyotrophic lateral sclerosis and other neurodegenerative disorders. CNS Drugs 2004; 18: 967–80
14. Tarnopolsky MA, et al. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology 2004; 62: 1771–7
15. Pline KA, Smith CL. The effect of creatine intake on renal function. Ann Pharmacother 2005; 39: 1093–6
16. Hersch SM, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2’dG. Neurology 2006; 66: 250–2
17. Bender A, et al. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology 2006; 67: 1262–4
18. Kley RA, et al. Creatine for treating muscle disorders. Available in The Cochrane Database of Systematic Reviews; Issu
1. Chichester: John Wiley; 2007 (accessed 18/04/08).

💊 Preparations

Proprietary Preparations

Arg.: Musashi Creatina†; Cz.: Neoton; Ital.: Creatile; Neoton†; Pol.: Neoton; Rus.: Neoton (Неотон). Multi-ingredient: Ital.: Fortium.
Published May 08, 2019.